A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose -Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children from 6 months to less than 5 years of Age with Neurogenic Detrusor Overactivity

Trial Profile

A Phase 3, Open-Label, Baseline-controlled, Multi-center, Sequential Dose -Titration Study to Assess the Pharmacokinetics, Long-Term Efficacy and Safety of Solifenacin Succinate Suspension in Children from 6 months to less than 5 years of Age with Neurogenic Detrusor Overactivity

Completed
Phase of Trial: Phase III

Latest Information Update: 26 May 2017

At a glance

  • Drugs Solifenacin (Primary)
  • Indications Overactive bladder
  • Focus Registrational; Therapeutic Use
  • Acronyms Marmoset
  • Sponsors Astellas Pharma BV
  • Most Recent Events

    • 26 Jan 2016 Status changed from suspended to completed as per ClinicalTrials.gov record.
    • 23 Oct 2015 Planned primary completion date changed from 1 Aug 2015 to 1 Dec 2015, according to ClinicalTrials.gov record.
    • 09 Oct 2014 Status changed from recruiting to suspended as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top